- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
- The current location of trastuzumab in the treatment of HER2 positive breast cancer2009 | First Faculty of Medicine
- Neratinib in the context of an early breast cancer anti-HER2 therapy2020 | First Faculty of Medicine
- Complete and long-term response of HER2 positive locally highly advanced metastatic breast cancer - case report2019 | Third Faculty of Medicine
- Trastuzumab emtansine in the treatment of residual HER2-positive breast cancer2019 | First Faculty of Medicine
- News in anti-HER2 targeted therapy in breast cancer2013 | First Faculty of Medicine
- Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression2017 | First Faculty of Medicine
- FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer2009 | Third Faculty of Medicine